Study Confirms Efficacy of ALK-Positive Lung Cancer Therapies in Real-World Settings

A recent study, analyzing insurance data from nearly 1,000 ALK-positive lung cancer patients, confirmed that real-world treatment outcomes align with clinical trial results. The research compared five tyrosine kinase inhibitors, highlighting alectinib's superior performance over crizotinib in patient survival and treatment duration. This reinforces alectinib's position as a primary treatment option.